Sanjna L Surya,Joseph Y Cheung,Sujal I Shah et al.
Sanjna L Surya et al.
Chirag A Buch,Nilam J Soni
Chirag A Buch
Addressing Alcohol Use [0.03%]
应对饮酒问题
Alex H Krist,Katharine A Bradley
Alex H Krist
Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype [0.03%]
美泊利单抗预防嗜酸性粒细胞性慢性阻塞性肺病加重的效果
Frank C Sciurba,Gerard J Criner,Stephanie A Christenson et al.
Frank C Sciurba et al.
Background: Mepolizumab is a humanized monoclonal antibody that targets interleukin-5, a cytokine that plays a central role in eosinophilic inflammation, which is present in 20 to 40% of patients with chronic obstructive ...
Lentiviral Gene Therapy for Severe Leukocyte Adhesion Deficiency Type 1 [0.03%]
lentivirus基因疗法治疗严重白细胞黏附分子缺陷病1型
Claire Booth,Julián Sevilla,Elena Almarza et al.
Claire Booth et al.
Background: The β2 common integrin subunit CD18 is essential for leukocyte-endothelial adhesion and extravasation to inflamed or infected tissue. Damaging variants in ITGB2, which encodes CD18, cause leukocyte adhesion d...
Laurent Martin,Darko Maric,Salam Idriss et al.
Laurent Martin et al.
Background: Secondary erythrocytosis often results from conditions that cause tissue hypoxia or an improper increase in erythropoietin (EPO) production. EPO, the major regulator of erythropoiesis, has a complex and tightl...
Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis [0.03%]
司美格鲁肽治疗代谢紊乱相关性非酒精性脂肪肝病的3期试验
Arun J Sanyal,Philip N Newsome,Iris Kliers et al.
Arun J Sanyal et al.
Background: Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). ...
Alice T Chen,Vivek H Murthy
Alice T Chen
Health Care in an Evolving Immigration Landscape - Providing Care while Upholding the Law [0.03%]
移民变迁中的医疗卫生保健：在遵守法律的同时提供医疗救助
Holland Kaplan,Anna Cabot,Peter Ubel
Holland Kaplan
Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer [0.03%]
既往接受过治疗的HER2突变型非小细胞肺癌患者的DSK生物学名口服抑制剂研究
John V Heymach,Gerrina Ruiter,Myung-Ju Ahn et al.
John V Heymach et al.
Background: Innovative oral targeted therapies are warranted for patients with human epidermal growth factor receptor 2 (HER2)-mutant non-small-cell lung cancer (NSCLC). Zongertinib is an oral, irreversible, HER2-selectiv...